This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prospective Liver Study

This study has been completed.
Information provided by (Responsible Party):
Hyun Kevin Kim, Emory University Identifier:
First received: February 15, 2012
Last updated: May 23, 2014
Last verified: May 2014
This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.

Liver Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prospective Analysis of Liver Cancer Treatment and Interventions

Resource links provided by NLM:

Further study details as provided by Hyun Kevin Kim, Emory University:

Primary Outcome Measures:
  • Assess efficacy of percutaneous and transarterial treatments for liver cancer. [ Time Frame: 1 month ]
    QOL questionnaire will be collected during follow up visit.

Secondary Outcome Measures:
  • long term follow up [ Time Frame: 3 months, 6 months 1year ]
    Patients will be administered QOL during 3 months, 6 months and 1 year follow up.

Enrollment: 400
Study Start Date: November 2008
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients 18 yrs and older with a diagnosis of Hepatocellular carcinoma and elegible for percutaneous liver treatments

Inclusion Criteria:

  • Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.

Exclusion Criteria:

  • Severe liver disfunction
  • Active uncontrolled infection
  • Significant underlying medical of physical illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01539993

United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Principal Investigator: Kevin S Kim, MD Emory University
  More Information

Responsible Party: Hyun Kevin Kim, MD FSIR, Director of Interventional Radiology and Image-Guided Medicine., Emory University Identifier: NCT01539993     History of Changes
Other Study ID Numbers: IRB00014768
Study First Received: February 15, 2012
Last Updated: May 23, 2014

Keywords provided by Hyun Kevin Kim, Emory University:
Hepatocellular carcinoma
Liver metastases
Percutaneous treatments

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases processed this record on September 21, 2017